Literature DB >> 23363497

Long-term functional outcomes after treatment for localized prostate cancer.

Matthew J Resnick1, Tatsuki Koyama, Kang-Hsien Fan, Peter C Albertsen, Michael Goodman, Ann S Hamilton, Richard M Hoffman, Arnold L Potosky, Janet L Stanford, Antoinette M Stroup, R Lawrence Van Horn, David F Penson.   

Abstract

BACKGROUND: The purpose of this analysis was to compare long-term urinary, bowel, and sexual function after radical prostatectomy or external-beam radiation therapy.
METHODS: The Prostate Cancer Outcomes Study (PCOS) enrolled 3533 men in whom prostate cancer had been diagnosed in 1994 or 1995. The current cohort comprised 1655 men in whom localized prostate cancer had been diagnosed between the ages of 55 and 74 years and who had undergone either surgery (1164 men) or radiotherapy (491 men). Functional status was assessed at baseline and at 2, 5, and 15 years after diagnosis. We used multivariable propensity scoring to compare functional outcomes according to treatment.
RESULTS: Patients undergoing prostatectomy were more likely to have urinary incontinence than were those undergoing radiotherapy at 2 years (odds ratio, 6.22; 95% confidence interval [CI], 1.92 to 20.29) and 5 years (odds ratio, 5.10; 95% CI, 2.29 to 11.36). However, no significant between-group difference in the odds of urinary incontinence was noted at 15 years. Similarly, although patients undergoing prostatectomy were more likely to have erectile dysfunction at 2 years (odds ratio, 3.46; 95% CI, 1.93 to 6.17) and 5 years (odds ratio, 1.96; 95% CI, 1.05 to 3.63), no significant between-group difference was noted at 15 years. Patients undergoing prostatectomy were less likely to have bowel urgency at 2 years (odds ratio, 0.39; 95% CI, 0.22 to 0.68) and 5 years (odds ratio, 0.47; 95% CI, 0.26 to 0.84), again with no significant between-group difference in the odds of bowel urgency at 15 years.
CONCLUSIONS: At 15 years, no significant relative differences in disease-specific functional outcomes were observed among men undergoing prostatectomy or radiotherapy. Nonetheless, men treated for localized prostate cancer commonly had declines in all functional domains during 15 years of follow-up. (Funded by the National Cancer Institute.).

Entities:  

Mesh:

Year:  2013        PMID: 23363497      PMCID: PMC3742365          DOI: 10.1056/NEJMoa1209978

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  29 in total

1.  Preliminary treatment considerations among men with newly diagnosed prostate cancer.

Authors:  Steven B Zeliadt; Carol M Moinpour; David K Blough; David F Penson; Ingrid J Hall; Judith Lee Smith; Donatus U Ekwueme; Ian M Thompson; Thomas E Keane; Scott D Ramsey
Journal:  Am J Manag Care       Date:  2010-05-01       Impact factor: 2.229

2.  Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment.

Authors:  Yolanda Pardo; Ferran Guedea; Ferrán Aguiló; Pablo Fernández; Víctor Macías; Alfonso Mariño; Asunción Hervás; Ismael Herruzo; María José Ortiz; Javier Ponce de León; Jordi Craven-Bratle; José Francisco Suárez; Ana Boladeras; Àngels Pont; Adriana Ayala; Gemma Sancho; Evelyn Martínez; Jordi Alonso; Montserrat Ferrer
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

3.  Should function and bother be measured and reported separately for prostate cancer quality-of-life domains?

Authors:  Bryce B Reeve; Arnold L Potosky; Gordon B Willis
Journal:  Urology       Date:  2006-09-18       Impact factor: 2.649

4.  Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.

Authors:  Konrad M Szymanski; John T Wei; Rodney L Dunn; Martin G Sanda
Journal:  Urology       Date:  2010-03-28       Impact factor: 2.649

5.  Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic.

Authors:  Kevin Rice; Jane Hudak; Kimberly Peay; Sally Elsamanoudi; Judith Travis; Robbin Lockhart; Jennifer Cullen; Libby Black; Susan Houge; Stephen Brassell
Journal:  Urology       Date:  2010-06-26       Impact factor: 2.649

6.  Health related quality of life for men treated for localized prostate cancer with long-term followup.

Authors:  George J Huang; Natalia Sadetsky; David F Penson
Journal:  J Urol       Date:  2010-06       Impact factor: 7.450

7.  Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE.

Authors:  Sara J Knight; David M Latini; Stacey L Hart; Natalia Sadetsky; Christopher J Kane; Janeen DuChane; Peter R Carroll
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

8.  Quality of life and satisfaction with outcome among prostate-cancer survivors.

Authors:  Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

9.  Predictors of patient preferences and treatment choices for localized prostate cancer.

Authors:  Benjamin D Sommers; Clair J Beard; Anthony V D'Amico; Irving Kaplan; Jerome P Richie; Richard J Zeckhauser
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

10.  Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.

Authors:  John L Gore; Lorna Kwan; Steve P Lee; Robert E Reiter; Mark S Litwin
Journal:  J Natl Cancer Inst       Date:  2009-06-09       Impact factor: 13.506

View more
  267 in total

1.  [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma].

Authors:  G Kristiansen; L Egevad; M Amin; B Delahunt; J R Srigley; P A Humphrey; J I Epstein
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

2.  Treatment of localized prostate cancer in elderly patients.

Authors:  Mohammed Haseebuddin; Marc C Smaldone
Journal:  Gland Surg       Date:  2015-08

3.  Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.

Authors:  Vincent Bouvet; Melinda Wuest; Justin J Bailey; Cody Bergman; Nancy Janzen; John F Valliant; Frank Wuest
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

Review 4.  Telemedicine and prostate cancer survivorship: a narrative review.

Authors:  Nnenaya Q Agochukwu; Ted A Skolarus; Daniela Wittmann
Journal:  Mhealth       Date:  2018-10-08

5.  Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care.

Authors:  Jennifer K Bernat; Daniela A Wittman; Sarah T Hawley; Daniel A Hamstra; Alexander M Helfand; David A Haggstrom; May Darwish-Yassine; Ted A Skolarus
Journal:  BJU Int       Date:  2015-10-26       Impact factor: 5.588

6.  Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment.

Authors:  Anne Holck Storås; Martin G Sanda; Montse Ferrer; Jon Håvard Loge; Alv A Dahl; Eivind A S Steinsvik; Ferran Guedea; Milada Cvancarova; Sophie D Fosså
Journal:  Clin Genitourin Cancer       Date:  2014-01-03       Impact factor: 2.872

7.  A Framework for Treatment Decision Making at Prostate Cancer Recurrence.

Authors:  Jane M Lange; Bruce J Trock; Roman Gulati; Ruth Etzioni
Journal:  Med Decis Making       Date:  2017-05-31       Impact factor: 2.583

Review 8.  Locally advanced prostate cancer: optimal therapy in older patients.

Authors:  Michael Froehner; Manfred P Wirth
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

Review 9.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

10.  The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.

Authors:  Ryan P Kopp; Lynn M Marshall; Patty Y Wang; Douglas C Bauer; Elizabeth Barrett-Connor; J Kellogg Parsons
Journal:  Eur Urol       Date:  2013-04-03       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.